Depression patient-derived cortical neurons for antidepressant selection
2021
GenetikaPlus Ltd, Jerusalem, Israel
Depressive disorders are widespread worldwide and affect a growing number of people every year. Current first-line antidepressants show only 37% remission, and their selection has been based on trial and error. This study uses in vitro models to develop a test method that provides patient-specific information on whether a patient will respond to a drug. Patient-derived lymphoblastoid cell lines from the "Sequenced Treatment Alternatives to Relieve Depression" study were used to generate cortical neurons and test them for the effect of bupropion, for which the donor patients showed remission or non-remission. Biomarkers specific to response to bupropion were identified, including synaptic connectivity and morphological changes, as well as specific changes in gene expression. These biomarkers support the concept of personalised antidepressant treatment based on in vitro platforms and could be used as predictors of patient response in the clinic.
Depression patient-derived cortical neurons reveal potential biomarkers for antidepressant response
Talia Cohen Solal
Added on: 03-27-2024
[1] https://www.nature.com/articles/s41398-021-01319-5
